ASXC FDA approval sell the leap options

١٩ مارس ٢٠٢١

ASXC has FDA approval for the surgical device granted this month.

ASXC has adequate cash for two year burn as sales are ramped up.

Sell the ASXC Jan 2023 leap options and the raw cost is $2 per share. Stock is as of today $3.80 range.

Invest the cash in GGN and trade GGN monthly into the dividend ex-date.

own the stock for nearly free at any cost in 21 months.

good product

small cap with adequate share count and volume.

reasonable speculation

see the links below...

all the best.

١ أبريل ٢٠٢١

ملاحظة

GGN up today with 2 weeks to monthly distribution dates.

Sold mine today...

not an April Fools day joke...